Location History:
- Melrose, FL (US) (1993)
- Franklin, TN (US) (1995 - 2002)
Company Filing History:
4 out of 1,163 
2 out of 2,106 
2 out of 1,217 
Years Active: 1993-2002
Title: The Innovative Contributions of Roy A. Jensen in Cancer Research
Introduction
Roy A. Jensen, based in Franklin, TN, has made significant strides in the field of cancer research through his innovative inventions. With a total of 9 patents to his name, Jensen's work focuses on methods for the detection and treatment of prevalent cancers such as breast and prostate cancer. His research has not only advanced the understanding of these diseases but has also paved the way for novel therapeutic approaches.
Latest Patents
Jensen's latest patents include a groundbreaking method for the detection and treatment of breast cancer. This invention centers on identifying differentially expressed genes in early, pre-invasive breast cancer tissue. By utilizing microscopically-directed tissue sampling techniques along with differential display or screening of cDNA libraries, Jensen demonstrates how genetic markers can indicate the presence of pre-invasive cancerous tissues. Moreover, he confirms the differential expression of genes through RT-PCR, nuclease protection assays, and in-situ hybridization of ductal carcinoma in situ tissue RNA and control tissue RNA.
Additionally, Jensen’s therapeutic methods for prostate cancer encompass gene therapy utilizing the BRCA family of genes, including BRCA1 and BRCA2, which play crucial roles in inhibiting the growth and tumorigenesis of prostate cancer cells. These methodologies represent significant advancements in cancer therapy and provide new avenues for treatment.
Career Highlights
Throughout his career, Roy A. Jensen has held positions at prestigious institutions, including Vanderbilt University and the University of Washington. His tenure at these institutions has contributed to the depth of his research and the breadth of his innovative approaches in oncology.
Collaborations
Collaboration has been a key aspect of Jensen's work, as he has partnered with notable individuals such as Jeffrey T. Holt and Cheryl L. Robinson-Benion. These collaborations have enriched his research and have facilitated the development of his patented methodologies.
Conclusion
Roy A. Jensen represents a pioneering force in the field of cancer research. His patents portray a commitment to advancing medical science through innovative solutions for cancer detection and treatment. With a career marked by collaboration and significant contributions, Jensen continues to inspire future generations in the fight against cancer.